Persistent Alopecia in a Breast Cancer Patient Following Taxane Chemotherapy and Adjuvant Endocrine Therapy: Case Report and Review of Post-treatment Hair Loss in Oncology Patients with Breast Cancer

接受紫杉烷类化疗和辅助内分泌治疗后乳腺癌患者出现持续性脱发:病例报告及乳腺癌肿瘤患者治疗后脱发的回顾

阅读:1

Abstract

Taxane chemotherapy and adjuvant endocrine therapy are commonly used in breast cancer patients following surgery. We describe a 59-year-old woman with a triple-positive invasive right breast cancer that was treated with surgery, radiation, chemotherapy, and adjuvant hormonal therapy. She subsequently developed scalp alopecia, with histopathological features of both androgenetic alopecia and alopecia areata; the hair loss did not resolve after completion of her chemotherapy. Significant clinical improvement was observed with topical minoxidil therapy. PubMed was searched for the following terms: alopecia, breast, cancer, chemotherapy, endocrine, hair, loss, minoxidil, permanent, and taxane. The papers containing these terms and their references were reviewed. Temporary hair loss is frequently observed following taxane chemotherapy; however, albeit uncommon, persistent or permanent alopecia may occur in women with breast cancer who have been treated with taxane chemotherapy and endocrine therapy. It may be reasonable to initiate therapy with topical minoxidil in breast cancer patients who develop alopecia after treatment with either taxane chemotherapy or endocrine therapy alone or both.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。